Search - tctmd.com

Displaying 1 - 20 of 120

Sort: Relevancy | Date

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Daily News

Barbershop Intervention for High BP Has Lasting Effects

Todd Neale

December 19, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

L.A. McKeown

December 06, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Aspirin Should Play Limited Role in Primary Prevention: Review

Michael O'Riordan

November 27, 2018

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

Presentation AHA 2018

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Presenter: Eric J Velazquez

November 12, 2018

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Advertisement

Top News in Endovascular Therapy: 2018

Top News in Prevention: 2018

Top News in Heart Failure: 2018

Barbershop Intervention for High BP Has Lasting Effects

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

NOACs Significantly Curb Risk of VTE in Cancer Patients

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

TCTMD’s Top 10 Most Popular Stories for November 2018

Aspirin Should Play Limited Role in Primary Prevention: Review

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

PIONEER Trial: Angiotensin Receptor-NeprilysinInhibition in Patients Hospitalized With Acute Decompensated Heart Failure

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content